PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain. / Pankratova, Stanislava; Nielsen, Birgit N; Shiraishi, Takehiko; Nielsen, Peter E.

In: International Journal of Oncology, Vol. 36, No. 1, 01.2010, p. 29-38.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Pankratova, S, Nielsen, BN, Shiraishi, T & Nielsen, PE 2010, 'PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain', International Journal of Oncology, vol. 36, no. 1, pp. 29-38. https://doi.org/10.3892/ijo_00000472

APA

Pankratova, S., Nielsen, B. N., Shiraishi, T., & Nielsen, P. E. (2010). PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain. International Journal of Oncology, 36(1), 29-38. https://doi.org/10.3892/ijo_00000472

Vancouver

Pankratova S, Nielsen BN, Shiraishi T, Nielsen PE. PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain. International Journal of Oncology. 2010 Jan;36(1):29-38. https://doi.org/10.3892/ijo_00000472

Author

Pankratova, Stanislava ; Nielsen, Birgit N ; Shiraishi, Takehiko ; Nielsen, Peter E. / PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain. In: International Journal of Oncology. 2010 ; Vol. 36, No. 1. pp. 29-38.

Bibtex

@article{18eb6b20fc4811de825d000ea68e967b,
title = "PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain",
abstract = "The Her-2 receptor coded for by the proto-oncogenic erbB-2 gene is a clinically validated target for treatment of a significant genetic subclass of breast cancers, and Her-2 is also overexpressed or mutated in a range of other cancers. In an approach to exploit antisense mediated splicing interference as a means of manipulating erbB-2 expression in a therapeutically relevant fashion, we have studied the effect on mRNA splicing of a series of peptide nucleic acid (PNA) oligomers targeting specific intron-exon junctions in the erbB-2 pre-mRNA. In particular, we are interested in identifying PNA oligomers that specifically induce skipping of exon 19 as this exon is coding for the ATP catalytic domain of Her-2, and if expressed such truncated version of the Her-2 protein should be functionally inactive in a dominant negative fashion. Therefore, antisense compounds having efficient erbB-2 exon 19 skipping activity could be very interesting in terms of drug discovery. In the present study we identified PNA oligomers having such activity in SK-BR-3 and HeLa cancer cells in culture.",
author = "Stanislava Pankratova and Nielsen, {Birgit N} and Takehiko Shiraishi and Nielsen, {Peter E}",
year = "2010",
month = jan,
doi = "10.3892/ijo_00000472",
language = "English",
volume = "36",
pages = "29--38",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

RIS

TY - JOUR

T1 - PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain

AU - Pankratova, Stanislava

AU - Nielsen, Birgit N

AU - Shiraishi, Takehiko

AU - Nielsen, Peter E

PY - 2010/1

Y1 - 2010/1

N2 - The Her-2 receptor coded for by the proto-oncogenic erbB-2 gene is a clinically validated target for treatment of a significant genetic subclass of breast cancers, and Her-2 is also overexpressed or mutated in a range of other cancers. In an approach to exploit antisense mediated splicing interference as a means of manipulating erbB-2 expression in a therapeutically relevant fashion, we have studied the effect on mRNA splicing of a series of peptide nucleic acid (PNA) oligomers targeting specific intron-exon junctions in the erbB-2 pre-mRNA. In particular, we are interested in identifying PNA oligomers that specifically induce skipping of exon 19 as this exon is coding for the ATP catalytic domain of Her-2, and if expressed such truncated version of the Her-2 protein should be functionally inactive in a dominant negative fashion. Therefore, antisense compounds having efficient erbB-2 exon 19 skipping activity could be very interesting in terms of drug discovery. In the present study we identified PNA oligomers having such activity in SK-BR-3 and HeLa cancer cells in culture.

AB - The Her-2 receptor coded for by the proto-oncogenic erbB-2 gene is a clinically validated target for treatment of a significant genetic subclass of breast cancers, and Her-2 is also overexpressed or mutated in a range of other cancers. In an approach to exploit antisense mediated splicing interference as a means of manipulating erbB-2 expression in a therapeutically relevant fashion, we have studied the effect on mRNA splicing of a series of peptide nucleic acid (PNA) oligomers targeting specific intron-exon junctions in the erbB-2 pre-mRNA. In particular, we are interested in identifying PNA oligomers that specifically induce skipping of exon 19 as this exon is coding for the ATP catalytic domain of Her-2, and if expressed such truncated version of the Her-2 protein should be functionally inactive in a dominant negative fashion. Therefore, antisense compounds having efficient erbB-2 exon 19 skipping activity could be very interesting in terms of drug discovery. In the present study we identified PNA oligomers having such activity in SK-BR-3 and HeLa cancer cells in culture.

U2 - 10.3892/ijo_00000472

DO - 10.3892/ijo_00000472

M3 - Journal article

C2 - 19956830

VL - 36

SP - 29

EP - 38

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -

ID: 16863233